Tecentriq 840 mg Injection
3 147,19$
2 454,81$
Tecentriq 840 mg Injection is an innovative immunotherapy used in the treatment of various cancers, including those affecting the lungs, urinary bladder, breast, and liver. This powerful anticancer agent functions by inhibiting the PD-L1 protein found on some cancer cells, a mechanism that enables these cells to escape detection by the immune system. By blocking PD-L1, Tecentriq empowers the body's immune response to identify and destroy cancer cells, potentially halting their growth or progression. It is essential to consult with a healthcare provider for appropriate use, as Tecentriq may cause immune-related side effects that require monitoring. This medication can be administered alone or in conjunction with other therapies, depending on the specific type of cancer being treated. As with any cancer treatment, potential patients should discuss their medical history and any existing conditions with their doctor to ensure safe usage. With its targeted approach, Tecentriq represents a significant advancement in cancer care, offering hope for improved outcomes in patients facing challenging diagnoses.
Quantité
Active Pharmaceutical Ingredient
Uses
• Tecentriq 840 mg injection is utilized in the treatment of early-stage non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy. It is recommended as an adjuvant therapy for patients whose tumors express PD-L1 on at least 1% of tumor cells. By inhibiting the PD-L1 protein, Tecentriq 840 mg injection helps activate the immune system to recognize and attack cancer cells. This approach aims to reduce the likelihood of cancer recurrence in patients with stage II to IIIA NSCLC.
• In the case of metastatic non-small cell lung cancer, Tecentriq 840 mg injection is administered in combination with bevacizumab, paclitaxel, and carboplatin. This combination is indicated as a first-line treatment option for patients diagnosed with metastatic non-squamous NSCLC. By enhancing the immune response against cancer cells, Tecentriq 840 mg injection plays a critical role in managing this advanced stage of lung cancer. The integration of this therapy aims to improve patient outcomes in a challenging clinical scenario.
• Tecentriq 840 mg injection is also indicated for the first-line treatment of extensive-stage small cell lung cancer when used in conjunction with carboplatin and etoposide. This combination therapy targets the aggressive nature of small cell lung cancer, which often presents at an advanced stage. The use of Tecentriq 840 mg injection helps to stimulate the immune system, offering a potential avenue for better management of this type of lung cancer. This treatment strategy is particularly important for patients facing limited options.
• For patients with urothelial carcinoma, Tecentriq 840 mg injection serves as a treatment option aimed at managing this type of cancer that originates in the urinary tract lining. This therapy can be particularly beneficial for individuals presenting with symptoms such as blood in urine or pain during urination. By utilizing Tecentriq 840 mg injection, healthcare providers can activate the body’s immune response to combat cancer cells effectively. This approach is essential for addressing the complexities of urothelial carcinoma in patients.
Benefits
Tecentriq 840 mg Injection is an immunotherapy drug that activates the body's immune system to fight cancer cells. It is used to treat various types of cancer, including lung cancer, bladder cancer, triple-negative breast cancer, and liver cancer. Tecentriq 840 mg Injection has been shown to improve overall immunity and survival in advanced-stage non-small cell lung cancer, triple-negative breast cancer, and bladder cancer. Compared to other anticancer medicines, Tecentriq 840 mg Injection is associated with very few side effects. It is important to note that the specific benefits of Tecentriq 840 mg Injection may vary depending on the type and stage of the cancer being treated, as well as the individual patient's overall health and medical history. Therefore, it is essential to discuss the potential benefits and risks of Tecentriq 840 mg with a doctor before starting treatment.
Side Effects
Like all medications, Tecentriq 840 mg Injection can cause side effects but do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.
Most Common Side Effects
• Nausea
• Constipation
• Breathlessness
• Decreased Appetite
• Coughing
Common Side Effects
• Black and Tarry Stools
• Fever
• Pain in Bladder
• Breathing Difficulty
• Diarrhoea
• Hair Loss
How To Use
Tecentriq 840 mg Injection is an intravenous infusion, Administered by a healthcare professional or nurse in a hospital or clinic setting. The specific dosing and administration of the Tecentriq 840 mg Injection will be determined by the patient's clinical condition, age, medical history, type of cancer and other factors. It is important to note that this Tecentriq 840 mg should not be self-administered, and it is important to follow the instructions of the healthcare professional administering the Tecentriq 840 mg.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Tecentriq 840 mg Injection. It may increase the risk of liver damage. It is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Tecentriq 840 mg Injection should be used with caution in patients with Kidney disease. It is important that patients with kidney disease closely monitor kidney function while taking Tecentriq 840 mg and report any unusual symptoms or changes in kidney function to their doctor. The dose of Tecentriq 840 mg Injection may need to be adjusted in patients with kidney disease.
• Breastfeeding: It is not recommended to breastfeed while taking Tecentriq 840 mg Injection. Tecentriq 840 mg may pass into breast milk and harm the infant. If you are breastfeeding and taking Tecentriq 840 mg Injection, it is essential to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor can help you make the best decision for you and your baby's health.
• Liver: Tecentriq 840 mg Injection should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Tecentriq 840 mg Injection and report any unusual symptoms or changes in liver function to their doctor. The dose of Benefits of Tecentriq 840 mg Injection may need to be adjusted in patients with liver disease.
• Pregnancy: Use of Tecentriq 840 mg Injection may be unsafe during pregnancy as animal studies indicate that it may harm the developing fetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Tecentriq 840 mg during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
• Driving: Tecentriq 840 mg Injection is unlikely to affect your ability to drive or operate machinery. If you experience any side effects while taking Tecentriq 840 mg such as dizziness or drowsiness, it is important to avoid driving or operating heavy machinery until the side effects have resolved.